Table 1.

A. Survival analysis (disease-specific survival). Chemotherapy-treated population. Univariate and multivariate analysis.

		Univariate analysis		Multivariate analysis
139 triple-negative breast cancer patients		DS-survival HR [95% CI]	p value	DS-survival HR [95% CI]	p value
Menopausal status	Pre	1
	Post	1.56 [0.95–2.55]	0.08
Tumor size (mm)	<20 mm	1
	>20 mm	1.03 [0.58–1.82]	0.92
Tumor grade	II	1
	III	1.23 [0.45–3.39]	0.69
Lymph node status	0	1
	1	0.84 [0.42–1.65]	0.61
NPI score	<5.4	1		1
	>5.4	2.15 [1.28–3.60]	0.003	2.30 [1.36–3.89]	0.002
Cellularity	Low	1
	Moderate	0.57 [0.22–1.46]	0.24
	High	0.59 [0.25–1.39]	0.23
P53 status	Wild-type	1
	Mutant	2.42 [1.15–5.09]	0.02
Immunity1 metagene expression	High	1
	Low	0.97 [0.60–1.58]	0.91
Immunity2 metagene expression	High	1		1
	Low	2.59 [1.54–4.34]	0.0002	2.68 [1.59–4.52]	0.0002
Proliferation/DNA damage metagene expression	High	1
	Low	1.13 [0.69–1.84]	0.63
AR-like metagene expression	High	1
	Moderate	1.07 [0.59–1.94]	0.82
	Low	0.98 [0.50–1.94]	0.96
Matrix/Invasion1 metagene expression	High	1
	Low	1.23 [0.76–2.01]	0.40
Matrix2 metagene expression	High	1
	Low	0.99 [0.61–1.61]	0.96

Abbreviations: NPI, Nottingham Prognostic Index; AR, androgen receptor; HR, hazard ratio; CI, confidence interval.